Sonnet BioTherapeutics Holdings, Inc. (SONN) Total Return Calculator with Dividends Reinvested

Sonnet BioTherapeutics Holdings, Inc.

Popular:

The total return for Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is +9.57% over the past 12 months. The 5-year total return is -99.98%, meaning $10,000 invested in SONN stock 5 years ago would be worth $2 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in SONN 1 year ago, it would be worth $10,161 today — you'd have gained $161.

With Dividends Reinvested$10,161+1.61%

Price Only (No DRIP)$10,161+1.61%

Period2025-06-30 → 2025-12-03

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in SONN

1Y$10,957+$957 (+9.6%)9.6% CAGR

3Y$103-$9,897 (-99.0%)-78.2% CAGR

5Y$2-$9,998 (-100.0%)-82.4% CAGR

10Y$0-$10,000 (-100.0%)-73.1% CAGR

15Y$0-$10,000 (-100.0%)-60.2% CAGR

20Y$0-$10,000 (-100.0%)-49.9% CAGR

30Y$0-$10,000 (-100.0%)-36.9% CAGR

Sonnet BioTherapeutics Holdings, Inc. did not pay dividends during this period. Total return = price return.

Loading SONN total return...

As of 2026-06-30

Performance Summary

Best Year+0.00%2015

Worst Year-93.18%2023

Max Drawdown-87.10%2025-07-15 → 2025-12-02

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
1Y	+9.57%	9.57%	+1.61%	+7.95 pp	$10,957
3Y	-98.97%	-78.23%	-98.62%	—	$103
5Y	-99.98%	-82.44%	-99.98%	—	$2
10Y	-100.00%	-73.08%	-100.00%	—	$0
15Y	-100.00%	-60.19%	-100.00%	—	$0
20Y	-100.00%	-49.88%	-100.00%	—	$0
30Y	-100.00%	-36.90%	-100.00%	—	$0

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2025	-21.25%	-21.25%	—	+16.64%	-37.9pp
2024	-89.63%	-89.63%	—	+24.00%	-113.6pp
2023	-93.18%	-93.18%	—	+24.81%	-118.0pp
2022	-81.22%	-81.22%	—	-19.95%	-61.3pp
2021	-91.02%	-91.02%	—	+28.79%	-119.8pp

SONN underperformed the S&P 500 by 11.28pp over the past year (+9.57% vs +20.84%).

Loading summary...

SONN Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
SONNSonnet BioTherapeutics Holdings, Inc.	$9M	—	—	+9.6%	—	-99.0%	-100.0%	-100.0%
ALDXAldeyra Therapeutics, Inc.	$124M	+17.1%	-59.3%	-43.3%	—	-74.7%	-83.1%	-64.2%
CRVSCorvus Pharmaceuticals, Inc.	$1.2B	+16.7%	+76.9%	+198.4%	—	+528.6%	+360.9%	-2.6%
IMMPImmutep Limited	$60M	-7.1%	-86.9%	-75.8%	—	-79.9%	-90.5%	-96.4%
NKTRNektar Therapeutics	$1.3B	+0.8%	+49.5%	+165.4%	—	+621.1%	-74.6%	-69.9%
SNDXSyndax Pharmaceuticals, Inc.	$1.9B	+11.2%	-6.2%	+116.7%	—	-4.9%	+10.1%	+87.4%
CLDXCelldex Therapeutics, Inc.	$2.5B	+19.1%	+25.1%	+56.0%	—	-4.4%	+5.6%	-48.3%
HALOHalozyme Therapeutics, Inc.	$9.2B	+16.0%	+1.2%	+32.0%	—	+104.2%	+56.2%	+743.0%
INCYIncyte Corporation	$22.9B	+18.5%	+6.9%	+57.2%	—	+72.3%	+25.9%	+40.9%
XNCRXencor, Inc.	$1.1B	+31.3%	-3.2%	+74.7%	—	-41.7%	-59.9%	+7.8%
CRLCharles River Laboratories International, Inc.	$10.9B	+24.8%	-0.2%	+36.2%	—	-2.0%	-44.9%	+151.5%

Compare:SONN vs ALDX SONN vs CRVS SONN vs IMMP SONN vs ALDX vs CRVS

About SONN Dividend Returns

Sonnet BioTherapeutics Holdings, Inc. (SONN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of SONN over the past year?

Sonnet BioTherapeutics Holdings, Inc. (SONN) delivered a return of 9.57% over the past year. Since SONN does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in SONN be worth today?

A $10,000 investment in Sonnet BioTherapeutics Holdings, Inc. one year ago would be worth $10,957 today, representing a gain of $957.

Q3Does SONN pay dividends?

Sonnet BioTherapeutics Holdings, Inc. (SONN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For SONN, the total return equals the price-only return.

Q4Did SONN beat the S&P 500?

No, Sonnet BioTherapeutics Holdings, Inc. (SONN) underperformed the S&P 500 by 11.28 percentage points over the past year. SONN delivered a total return of 9.57%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed SONN by 11.28pp during this period.

Q5What is SONN's worst drawdown?

Sonnet BioTherapeutics Holdings, Inc. (SONN) experienced a maximum drawdown of -87.10% over the past year, declining from its peak on 2025-07-15 to its trough on 2025-12-02. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is SONN's long-term total return over 10, 20, or 30 years?

Here are Sonnet BioTherapeutics Holdings, Inc. (SONN)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-73.1% CAGR) — $10,000 would have grown to $0. Over 20 years: -100.0% total return (-49.9% CAGR) — $10,000 → $0. Over 30 years: -100.0% total return (-36.9% CAGR) — $10,000 → $0. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was SONN's best and worst year?

Sonnet BioTherapeutics Holdings, Inc.'s best calendar year was 2015 with a total return of 0.0%. Its worst year was 2023 with a total return of -93.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 93.2 percentage points.

How much would $100/month in SONN be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →